Jyong Biotech Ltd (MENS)

Dec 30, 2025

Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat

Dec 30, 2025

Dec 29, 2025

After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st

Dec 29, 2025

Dec 22, 2025

Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat

Dec 22, 2025

Dec 21, 2025

Jyong Biotech Ltd.(NasdaqGM: MENS) added to NASDAQ Biotechnology Index - marketscreener.com

Dec 21, 2025

Dec 19, 2025

Jyong Biotech addresses share price fluctuations amid lock-up expiry By Investing.com - Investing.com Nigeria

Dec 19, 2025

Dec 19, 2025

Jyong Biotech 'not aware' of any material information amid share price movement - MSN

Dec 19, 2025

Dec 19, 2025

Jyong Biotech in Talks With Funds Interested in Buying Shares - marketscreener.com

Dec 19, 2025

Dec 19, 2025

Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com

Dec 19, 2025

Dec 19, 2025

Jyong Biotech in talks with investment funds for purchasing co's ordinary shares - marketscreener.com

Dec 19, 2025

Dec 19, 2025

Jyong Biotech ‘not aware’ of any material information amid share price movement - TipRanks

Dec 19, 2025

Dec 19, 2025

Jyong Biotech Responds to Share Price and Volume Movement - The Manila Times

Dec 19, 2025

Dec 17, 2025

Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week LowHere's Why - MarketBeat

Dec 17, 2025

Dec 17, 2025

Small U.S. Stocks Decrease; Jyong Biotech Falls Furthest - 富途牛牛

Dec 17, 2025

Dec 17, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Dec 17, 2025

Dec 16, 2025

Small U.S. Stocks Close Lower; Jyong Biotech Falls Furthest - 富途牛牛

Dec 16, 2025

Dec 16, 2025

Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3%Here's What Happened - MarketBeat

Dec 16, 2025

Dec 15, 2025

Jyong Biotech (NASDAQ:MENS) Shares Gap DownWhat's Next? - MarketBeat

Dec 15, 2025

Dec 14, 2025

Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2025. - marketscreener.com

Dec 14, 2025

Dec 10, 2025

Jyong Biotech Shares Becomes Oversold (MENS) - Nasdaq

Dec 10, 2025

Dec 10, 2025

Jyong Biotech (NASDAQ:MENS) Trading Down 5.9%Here's Why - MarketBeat

Dec 10, 2025

Dec 08, 2025

Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - MarketBeat

Dec 08, 2025

Dec 08, 2025

Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World

Dec 08, 2025

Dec 07, 2025

Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World

Dec 07, 2025

Dec 06, 2025

Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia

Dec 06, 2025

Dec 05, 2025

Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat

Dec 05, 2025

Dec 04, 2025

Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com

Dec 04, 2025

Dec 04, 2025

Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView — Track All Markets

Dec 04, 2025

Dec 04, 2025

Jyong Biotech Expands Regional Partnerships, Signs MOU with - GlobeNewswire

Dec 04, 2025

Dec 02, 2025

Jyong Biotech (MENS) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 02, 2025

Jyong Biotech (NASDAQ:MENS) Trading Up 15.1%Here's What Happened - MarketBeat

Dec 02, 2025

Nov 27, 2025

Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha

Nov 27, 2025

Nov 26, 2025

Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat

Nov 26, 2025

Nov 26, 2025

Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia

Nov 26, 2025

Nov 25, 2025

Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Australia

Nov 25, 2025

Nov 24, 2025

Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - marketscreener.com

Nov 24, 2025

Nov 24, 2025

Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa

Nov 24, 2025

Nov 24, 2025

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times

Nov 24, 2025

Nov 24, 2025

Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan

Nov 24, 2025

Nov 23, 2025

MCS-8, a Plant-Derived Drug, Reduces Prostate Cancer Incidence vs Placebo - CancerNetwork

Nov 23, 2025

Nov 21, 2025

Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat

Nov 21, 2025

Nov 21, 2025

Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance

Nov 21, 2025

Nov 21, 2025

Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance

Nov 21, 2025

Nov 20, 2025

Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria

Nov 20, 2025

Nov 20, 2025

Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria

Nov 20, 2025

Nov 20, 2025

Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa

Nov 20, 2025

Nov 20, 2025

Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - marketscreener.com

Nov 20, 2025

Nov 20, 2025

Jyong Biotech announces completion of primary endpoint statistical analysis for phase II clinical trial of MCS-8 with positive outcomes - MarketScreener

Nov 20, 2025